急性症状性癫痫发作的预后与管理:一项前瞻性、多中心、观察性研究
这项前瞻性、多中心、观察性研究纳入年龄≥18岁、首次急性症状性癫痫发作且排除癫痫持续状态的患者,随访12个月,主要终点为首次非诱发性癫痫复发。结构性病因者122例中11例复发,累积12个月风险10.7%(95%CI 4.7%-16.7%);非结构性病因19例无一复发。感染合并结构性病因与复发独立相关(OR 11.1;95%CI 1.8-69.7)。抗癫痫治疗中位时长3.4个月(IQR 0-9.3),11例复发中7例仍在服药,更长疗程未降低复发风险;德国神经重症医生的匿名在线调查(非代表性)中多数认为≤3个月足够。作者认为无高危特征时应早期停用抗癫痫药物以避免过度治疗。
要点
- 结构性病因首次急性症状性发作后12个月非诱发性复发累积风险10.7%(95%CI 4.7%-16.7%),低于预设的≤25%假设。
- 非结构性病因19例随访12个月无一例非诱发性复发。
- 感染合并结构性病因较单纯结构性病因独立增加复发风险(OR 11.1;95%CI 1.8-69.7)。
- 11例复发中7例发生在服用抗癫痫药物期间,更长治疗时长与非诱发性复发风险降低无关。
- 抗癫痫治疗中位时长3.4个月(IQR 0-9.3);非代表性在线调查中多数神经重症医生认为≤3个月足够。
适用人群与场景
- 年龄≥18岁、首次急性症状性癫痫发作的患者;排除癫痫持续状态患者。
- 神经重症监护场景中出现的急性症状性癫痫发作。
处置流程与药物剂量
- 抗癫痫治疗中位持续时间3.4个月(IQR 0-9.3)。
- 作者认为:无高危特征时应早期停用抗癫痫药物以避免过度治疗;应识别复发风险增高的个体情况,如引起结构性脑损伤的中枢神经系统感染。
- 非代表性在线调查中,多数德国神经重症医生认为抗癫痫药物治疗3个月或更短时间即足够。
研究设计与关键结果
- 研究类型:前瞻性、多中心、观察性研究;样本量122例结构性病因患者和19例非结构性病因患者;人群为年龄≥18岁首次急性症状性癫痫发作且排除癫痫持续状态者;随访12个月。
- 主要终点:结构性病因者122例中11例出现非诱发性癫痫复发,累积12个月风险10.7%(95%CI 4.7%-16.7%);非结构性病因19例中无一例后续非诱发性发作。
- 与单纯结构性病因相比,感染合并结构性病因与非诱发性癫痫复发独立相关(OR 11.1;95%CI 1.8-69.7)。
- 抗癫痫治疗中位时长3.4个月(IQR 0-9.3);11例复发者中7例在服用抗癫痫药物期间复发;更长治疗时长与非诱发性癫痫复发风险降低无关。
- 对德国神经重症医生的匿名在线调查(非代表性)显示,多数认为抗癫痫药物治疗3个月或更短时间足够。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、观察性研究;在线调查为非代表性调查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:即使结构性病因,急性症状性癫痫发作后非诱发性发作风险也低,仍无证据支持长期抗癫痫药物治疗。
- 作者建议:应识别非诱发性癫痫复发风险增高的个体情况,如引起结构性脑损伤的中枢神经系统感染。
- 作者认为:无高危特征时,应早期停用抗癫痫药物以避免过度治疗。
- 非代表性在线调查显示多数神经重症医生认为抗癫痫治疗≤3个月足够,但该调查不构成推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute symptomatic epileptic seizures are frequently seen in neurocritical care. To prevent subsequent unprovoked seizures, long-term treatments with antiseizure medications are often initiated although supporting evidence is lacking. This study aimed at prospectively assessing the risk of unprovoked seizure relapse with respect to the use of antiseizure medications. It was hypothesized that after a first acute symptomatic seizure of structural etiology, the cumulative 12-month risk of unprovoked seizure relapse is ≤ 25%.
METHODS: Inclusion criteria were age ≥ 18 and acute symptomatic first-ever epileptic seizure; patients with status epilepticus were excluded. Using telephone and mail interviews, participants were followed for 12 months after the acute symptomatic first seizure. Primary endpoint was the occurrence and timing of a first unprovoked seizure relapse. In addition, neuro-intensivists in Germany were interviewed about their antiseizure treatment strategies through an anonymous online survey.
RESULTS: Eleven of 122 participants with structural etiology had an unprovoked seizure relapse, resulting in a cumulative 12-month risk of 10.7% (95%CI, 4.7%-16.7%). None of 19 participants with a non-structural etiology had a subsequent unprovoked seizure. Compared to structural etiology alone, combined infectious and structural etiology was independently associated with unprovoked seizure relapse (OR 11.1; 95%CI, 1.8-69.7). Median duration of antiseizure treatment was 3.4 months (IQR 0-9.3). Seven out of 11 participants had their unprovoked seizure relapse while taking antiseizure medication; longer treatment durations were not associated with decreased risk of unprovoked seizure relapse. Following the non-representative online survey, most neuro-intensivists consider 3 months or less of antiseizure medication to be adequate.
CONCLUSIONS: Even in case of structural etiology, acute symptomatic seizures bear a low risk of subsequent unprovoked seizures. There is still no evidence favoring long-term treatments with antiseizure medications. Hence, individual constellations with an increased risk of unprovoked seizure relapse should be identified, such as central nervous system infections causing structural brain damage. However, in the absence of high-risk features, antiseizure medications should be discontinued early to avoid overtreatment.
参考来源
- Herzig-Nichtweiß J, Salih F, Berning S, et al. Prognosis and management of acute symptomatic seizures: a prospective, multicenter, observational study. Ann Intensive Care. 2023. PMID: 37712992. doi:10.1186/s13613-023-01183-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。